ATS GUIDELINES Bundle

Drug-Resistant Tuberculosis

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/1206585

Contents of this Issue

Navigation

Page 1 of 15

2 Key Points ➤ In this pocket guide, the guideline committee provides new recommendations for treatment of multiple drug-resistant tuberculosis (MDR-TB) and for treatment of isoniazid-resistant-TB. • MDR-TB is defined specifically as resistance to at least isoniazid and rifampin, the two most important first-line drugs. ➤ The guideline is intended for settings in which treatment is individualized and where mycobacterial cultures, molecular (genotypic) and culture-based (phenotypic) drug susceptibility tests (DSTs), and radiographic facilities are available. ➤ Treatment success was most likely with regimens for MDR-TB containing 5 effective drugs in the intensive phase. Mortality was also significantly reduced for those taking 5 or 6 effective drugs. Definitions MDR-TB Resistance to at least isoniazid and rifampin pre-XDR-TB A subset of MDR-TB with additional resistance to one but not both fluoroquinolone and a second-line injectable agent Extensively drug-resistant tuberculosis (XDR-TB) A subset of MDR-TB with additional resistance to both a fluoroquinolone and a second-line injectable agent

Articles in this issue

view archives of ATS GUIDELINES Bundle - Drug-Resistant Tuberculosis